Sk Biopharmaceuticals Co Ltd (326030) — Working Capital to Net Assets Ratio
Sk Biopharmaceuticals Co Ltd (326030) has a Working Capital to Net Assets ratio of 47.0% as of December 2025. Working capital of ₩388.03 Billion (current assets of ₩683.23 Billion minus current liabilities of ₩295.20 Billion) is measured against net assets of ₩826.27 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See Sk Biopharmaceuticals Co Ltd (326030) balance sheet quality index to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Sk Biopharmaceuticals Co Ltd Working Capital to Net Assets (2016–2025)
This chart shows how Sk Biopharmaceuticals Co Ltd's Working Capital to Net Assets ratio has evolved across 10 annual periods from 2016 to 2025. As of December 2025, the ratio stands at 47.0%, reflecting working capital of ₩388.03 Billion against net assets of ₩826.27 Billion KRW. Check Sk Biopharmaceuticals Co Ltd tangible book value ratio to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for Sk Biopharmaceuticals Co Ltd (2016–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Sk Biopharmaceuticals Co Ltd from 2016 to 2025, covering 10 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see 326030 company net worth.
| Year | WC/NA Ratio | Working Capital (KRW) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 47.0% | ₩388.03 Billion | ₩826.27 Billion | ₩683.23 Billion | ₩295.20 Billion | ▲ +2.5 pp |
| 2024 | 44.4% | ₩255.10 Billion | ₩573.98 Billion | ₩651.37 Billion | ₩396.28 Billion | ▼ -32.5 pp |
| 2023 | 77.0% | ₩247.10 Billion | ₩320.95 Billion | ₩488.72 Billion | ₩241.62 Billion | ▼ -25.6 pp |
| 2022 | 102.6% | ₩324.85 Billion | ₩316.56 Billion | ₩487.92 Billion | ₩163.07 Billion | ▲ +29.9 pp |
| 2021 | 72.7% | ₩322.91 Billion | ₩444.19 Billion | ₩471.22 Billion | ₩148.31 Billion | ▼ -23.3 pp |
| 2020 | 96.0% | ₩364.01 Billion | ₩379.07 Billion | ₩434.60 Billion | ₩70.60 Billion | ▼ -264.5 pp |
| 2019 | 360.5% | ₩-46.96 Billion | ₩-13.03 Billion | ₩98.68 Billion | ₩145.64 Billion | ▲ +274.2 pp |
| 2018 | 86.3% | ₩50.59 Billion | ₩58.63 Billion | ₩81.56 Billion | ₩30.97 Billion | ▲ +12.5 pp |
| 2017 | 73.8% | ₩34.85 Billion | ₩47.24 Billion | ₩81.83 Billion | ₩46.98 Billion | ▼ -16.5 pp |
| 2016 | 90.3% | ₩133.38 Billion | ₩147.69 Billion | ₩174.94 Billion | ₩41.57 Billion | — |